nominally significantp ≤ 0.05
We detected nominally significant changes in PC1 in the semaglutide group and in PC5 in the empagliflozin group (repeated measures ANOVA, p ≤ 0.05).
We detected nominally significant changes in PC1 in the semaglutide group and in PC5 in the empagliflozin group (repeated measures ANOVA, p ≤ 0.05).